The Cole Foundation continues

to support the Montreal Medical Research Community and the Montreal Theatre Community.

Cole Foundation commits an additional $1.75 million to research in pediatric and young adult leukemia & lymphoma

Montreal, May 10, 2013 – For a sixth consecutive year, promising young scientists will receive subsidies for their research on leukemia and lymphomas in children and young adults. A set of generous fellowship grants from the Cole Foundation, amounting to nearly $520,000, will be awarded for the period from 2013 to 2015 to 10 scientists whose research is devoted to pediatric leukemia and lymphoma. In addition to this component, there is the Cole Foundation New Investigator Program, under which nine new Principal Investigators will receive funding totalling $1.2 million. The new grants will be spread over three years and provide $50,000 annually in support of their ongoing research. In all, the Cole Foundation has committed an additional $1.75 million to research in 2013.

“It’s important for the Cole Foundation to help develop the next generation of researchers,” said Barry Cole, who is President of the foundation. “The medical faculties at the Université de Montréal and McGill University, as well as the Institut national de recherche scientifique (INRS) – Institut Armand-Frappier are working very hard to find a way of winning the fight against pediatric cancer and we’re glad to be able to contribute through our grants to young researchers.”

“The Cole Foundation supports research projects from talented young scientists who aim to contribute to the advancement of the fight against pediatric leukemia, said Dr. Helen Boisjoly, Dean of the Faculty of Medicine at the Université de Montréal. The contribution of these scholarships is crucial for UdeM researchers who were selected this year.”

“The sustained support from the Cole Foundation gives an important boost to the research being conducted in this area at McGill and across our sister universities and institutes in Quebec.” said Dr. David Eidelman, Vice-Principal (Health Affairs) and Dean of Medicine. “Not only does it help us stay at the forefront through the work of our promising researchers, it models the type of partnerships that are so important in advancing discovery for society.”

In connection with its announcement of the grants, the Cole Foundation also organized a day of discussions on the state of research in the field of pediatric cancer. Guest speaker for the occasion was Dr. David Malkin of the SickKids Hospital, in Toronto. In a stimulating talk addressed to the general public and the Montreal medical community at large, Dr. Malkin told his audience that victory in the fight against several forms of cancer is near, but still depends heavily on basic research.

About the Cole Foundation

The Cole Foundation offers two-year fellowships to clinical, doctoral and postdoctoral graduate scientists dedicated to research in leukemia and leukemia-related diseases in children and young adults. Through its fellowships, the Cole Foundation has committed more than $6 million to support leukemia researchers in Greater Montreal laboratories and hospitals. The Cole Foundation was created in 1980 by the late businessman John N. (Jack) Cole to support Montreal-based research in pediatric oncology and hematology. He established the Penny Cole Laboratory at the Montreal Children’s Hospital and the Jack Cole Chair in Pediatric Oncology and Hematology at McGill University.

Cole Foundation Research Fellowships (2013–2015)

Université de Montréal

Damien Grapton, IRCM, Experimental Medicine
Project: Study of the role of a variant form of GFI1 (GFI136N) in the development of acute myeloblastic leukemia

Arhamatoulaye Maiga, IRIC, Biochemistry
Project: G protein coupled receptors (GPCR); Acute myeloid leukemia (AML); Chemical screening: Therapeutic targeting; Transcriptome

Bastien Gerby, IRIC, Hematopoiesis and leukemia research
Project: Towards targeted therapy of T-acute lymphoblastic leukemia

Hiba Zahreddine, IRIC, Pathology and Cell Biology
Project: Understanding clinical resistance to ribavirin in M4/M5 acute myeloid leukemia patients

Elizabeth Krakow, Maisonneuve-Rosemont Hospital, Hematology-Oncology
Project: Adoptive transfer of alloreactive cells to treat poor-prognosis acute myeloid leukemia (ATAC-AML-01)

Magalie Celton, IRIC, Medicine
Project: Identification and investigation of the collaborating molecular events in pediatric acute myeloid leukemia with MLL-AF9 translocation

Jean-Philippe Guégan, IRIC, Pharmacology
Project: Roles of the TC21 MAPK pathway in the development and progress of myeloid leukemias

Camille Simon, IRIC, Medicine
Project: The Polycomb repressive complex 2 (PRC2): A mechanistic investigation of its role in normal and leukemic stem cells

McGill University

Alicia Bolt, Lady Davis Institute, Experimental Medicine/Oncology
Project: The role of tungsten in preB acute lymphoblastic leukemogenesis

Julie Ross, IRCM, Experimental Medicine
Project: Role of the BTB/POZ domain protein Miz-1 in the development of B-cell lymphoma

Cole Foundation New Investigator Program

Noel Raynal, Sainte-Justine Hospital Research Center
Projet: Epigenetic aberrations and epigenetic chemotherapy in pediatric leukemia

Kolja Eppert, Montreal Children’s Hospital Research Centre
Project: Pediatric Acute Myeloid Leukemia (AML) – Leukemia Stem Cells

Frederick Mallette, Maisonneuve-Rosemont Hospital Research Center
Project: The role of cellular senescence in prevention and treatment of pediatric leukemia

Geraldine Delbès, INRS–Institut Armand-Frappier
Project: Effects of chemotherapies used to treat paediatric cancers on male fertility

Moutih Rafei, Université de Montréal, Pharmacology
Project: Interleukin-21: A New Thymopoietic Elixir

Jean-Sebastien Delisle, Maisonneuve-Rosemont Hospital Research Center
Project: Adoptive immunotherapy for leukemia

Laurent Sabbagh, Maisonneuve-Rosemont Hospital Research Center
Project: Characterization of novel survival pathways in leukemia and lymphoma: Potential new targets for therapy

Gilles Hickson, Sainte-Justine Hospital Research Center
Project: Mechanisms of cell division in leukemia and lymphoma

Hugo Wurtele, Maisonneuve-Rosemont Hospital Research Center
Project: Understanding the mechanism of action of HDAC Inhibitors to improve Childhood Leukemia treatment


McGill Faculty of Medicine:
Faculté de médecine de l’Université de Montréal:
INRSInstitut Armand-Frappier:

This entry was posted in Press Releases on May 10, 2013.